Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Arcutis Biotherapeutics (ARQT) Research & Development (2021 - 2025)

Historic Research & Development for Arcutis Biotherapeutics (ARQT) over the last 5 years, with Q3 2025 value amounting to $19.6 million.

  • Arcutis Biotherapeutics' Research & Development rose 52.82% to $19.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $71.1 million, marking a year-over-year decrease of 1707.4%. This contributed to the annual value of $76.4 million for FY2024, which is 3088.85% down from last year.
  • Arcutis Biotherapeutics' Research & Development amounted to $19.6 million in Q3 2025, which was up 52.82% from $19.5 million recorded in Q2 2025.
  • Over the past 5 years, Arcutis Biotherapeutics' Research & Development peaked at $69.7 million during Q3 2022, and registered a low of $14.5 million during Q4 2024.
  • For the 5-year period, Arcutis Biotherapeutics' Research & Development averaged around $30.1 million, with its median value being $25.2 million (2023).
  • Its Research & Development has fluctuated over the past 5 years, first soared by 8779.53% in 2022, then tumbled by 6237.54% in 2023.
  • Arcutis Biotherapeutics' Research & Development (Quarter) stood at $52.6 million in 2021, then plummeted by 35.54% to $33.9 million in 2022, then fell by 29.82% to $23.8 million in 2023, then tumbled by 39.1% to $14.5 million in 2024, then skyrocketed by 35.39% to $19.6 million in 2025.
  • Its Research & Development stands at $19.6 million for Q3 2025, versus $19.5 million for Q2 2025 and $17.5 million for Q1 2025.